Sarepta Therapeutics (SRPT) Interest Expenses (2017 - 2022)

Sarepta Therapeutics has reported Interest Expenses for 6 years, with the latest figure at $12.7 million in Q4 2022.

• For the quarter ending Q4 2022, Interest Expenses fell 20.86% year-over-year to $12.7 million; the trailing twelve-month figure through Sep 2023 stood at $12.7 million (down 80.01% YoY), and the FY2023 full-year result was $22.0 million, down 58.67% from the prior year.
• Interest Expenses for Q4 2022 stood at $12.7 million, down from $14.7 million in the prior quarter.
• The five-year high for Interest Expenses was $20.6 million in Q3 2021, with the low at $172000.0 in Q1 2019.
• Average Interest Expenses over 5 years is $10.7 million, with a median of $12.6 million recorded in 2020.
• Year-over-year, Interest Expenses plunged 97.75% in 2019 and jumped 7815.7% in 2020.
• Tracing SRPT's Interest Expenses over 5 years: stood at $2.3 million in 2018, then jumped by 263.05% to $8.4 million in 2019, then grew by 28.18% to $10.8 million in 2020, then jumped by 49.23% to $16.0 million in 2021, then retreated by 20.86% to $12.7 million in 2022.
• The last three Interest Expenses figures came in at $12.7 million (Q4 2022), $14.7 million (Q3 2022), and $17.0 million (Q2 2022), per Business Quant data.

Peer Comparison